Cadrenal Therapeutics

CVKD

Current ValuationThe current P/E ratio is -0.30, above the reasonable range, cheaper than 0.89% of the time in the past 3 years, and the industry ranks 79/256, the industry Median -1.13.

-0.3xP/E
Stock price$0.97Earnings per share$-3.24

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-61.57x154.30%$64.32B
BAYRYUSBayer
-24.19x--$48.73B
BAYZFUSBayer Aktiengesellschaft
-24.08x--$48.51B
VTRSUSViatris
-51.68x107.68%$21.23B
ELANUSElanco Animal Health
-56.97x129.36%$11.34B
AXSMUSAxsome Therap
-42.66x21.12%$8.18B
VREOFUSVIREO GROWTH INC
-120.44x--$8.08B
CURLFUSCuraleaf Holdings, Inc.
-119.47x--$6.22B
BLTEUSBelite Bio
-59.12x29.87%$6.05B
MANEUSVeraDermics
-55.48x97.44%$5.79B
RGCUSRegencell Bioscience
-415.37x--$4.86B
DFTXUSDefinium Therapeutics
-13.67x54.55%$4.84B
EWTXUSEdgewise Therapeutics
-22.02x207.38%$4.34B
AMLXUSAmylyx Pharmaceuticals
-23.58x1.76%$3.59B
TARSUSTarsus Pharmaceuticals
-68.06x256.39%$3.16B
ELVNUSEnliven Therapeutics
-29.00x5.59%$3.07B
SUPNUSSupernus Pharma
-22.25x66.18%$2.45B
MBXUSMBX Biosciences
-23.30x31.12%$2.43B
BHCUSBausch Health
-2.21x569.84%$2.43B
PRGOUSPerrigo
-1.31x100.10%$2.27B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.